A Zofran pump is a small, portable device that continuously delivers ondansetron (brand name Zofran) through a tiny needle placed just under the skin. It’s primarily used for pregnant people experiencing severe nausea and vomiting that hasn’t responded to oral medications. The pump provides a steady, low dose of the anti-nausea drug throughout the day, bypassing the stomach entirely, which matters when someone is too nauseated to keep pills down.
How the Pump Works
The device is compact enough to clip onto clothing or tuck into a pocket. A small, flexible catheter connects the pump to a needle inserted just beneath the skin, usually in the thigh or abdomen. The pump delivers ondansetron subcutaneously, meaning the medication absorbs slowly through the fatty tissue under the skin rather than going through the digestive system.
Most Zofran pumps deliver medication in two ways. A continuous “basal” rate provides a constant trickle of medication around the clock. On top of that, the patient can press a button to receive a small extra dose (called a bolus) when nausea spikes. This combination keeps a baseline level of the drug in the bloodstream while allowing flexibility for breakthrough symptoms. Oral ondansetron is typically dosed at up to 8 mg three to four times daily, and the pump aims to achieve similar or lower total doses spread more evenly throughout the day.
Who Gets a Zofran Pump
The pump is almost exclusively prescribed for hyperemesis gravidarum, which is the severe end of pregnancy-related nausea and vomiting. This isn’t ordinary morning sickness. Hyperemesis gravidarum involves persistent vomiting that leads to dehydration, weight loss, and sometimes hospitalization. A Zofran pump is generally considered only after other treatments have failed, including oral anti-nausea medications, dietary changes, and sometimes IV fluids.
The therapy is still considered experimental by some in the medical community. A 2012 review of the available evidence concluded that randomized controlled trials are needed before continuous subcutaneous ondansetron can be widely recommended, and that coverage should be restricted to cases of intractable hyperemesis gravidarum unresponsive to conventional treatment. In practice, though, many specialists do prescribe it for patients who have exhausted other options.
What the Experience Is Like
A home health nurse typically places the pump and teaches you how to manage it. The needle site needs to be rotated every 24 to 72 hours to prevent irritation. You’ll usually insert the new site yourself after being trained, though some patients have a nurse visit for each change.
The pump stays on continuously, including during sleep. Most people wear it for weeks or even months, depending on how long the severe nausea lasts. Many patients with hyperemesis gravidarum see improvement in the second trimester, at which point they can be weaned off the pump gradually. The device itself is small and discreet enough to wear under clothing, though it does require carrying the pump unit and checking the medication reservoir periodically.
How Well It Works
Case series data shows that 64% to 75% of patients using continuous subcutaneous ondansetron experienced complete resolution of their symptoms. That’s a meaningful success rate for a population that, by definition, hasn’t responded to other treatments. A matched comparison also found that ondansetron delivered this way was significantly better tolerated than another common anti-nausea drug given the same way, with only 4.4% of ondansetron patients experiencing tolerability problems compared to 31.8% on the alternative.
That said, the evidence base has important limitations. The studies are retrospective and observational, without the kind of randomized controlled trials that would provide the strongest proof. Complications arose in roughly 25% to 30% of cases in available studies, sometimes severe enough to require stopping the therapy. These complications included worsening symptoms and side effects from the medication itself.
Side Effects and Risks
The most common issue specific to pump delivery is irritation at the needle site. Pain, redness, or burning where the needle sits can develop, especially if the site isn’t rotated frequently enough. Keeping the area clean and changing insertion spots regularly helps minimize this.
Ondansetron itself carries some side effects regardless of how it’s delivered. Constipation and headache are the most frequently reported. At higher doses, ondansetron can affect heart rhythm by prolonging what’s called the QT interval, a measurement of electrical activity in the heart. In rare cases, this can lead to a dangerous irregular heartbeat. Your provider will likely assess your heart rhythm risk before starting the pump. Serious allergic reactions including difficulty breathing and facial swelling are rare but possible.
Safety During Pregnancy
The safety profile of ondansetron during pregnancy has been studied extensively. Research has not found a higher chance of miscarriage, preterm delivery, or low birth weight when ondansetron was used during pregnancy. Most studies among thousands of pregnancies have not reported an increased chance of birth defects either. Ondansetron was originally developed to treat nausea from chemotherapy, surgery, and radiation, and its use in pregnancy is considered off-label, meaning it’s prescribed based on clinical judgment rather than a specific FDA approval for that purpose.
Cost and Insurance Coverage
A Zofran pump can be expensive. The medication, pump supplies, and home nursing visits add up quickly, and early analyses described the therapy as cost-prohibitive compared to other treatment methods for pregnancy nausea. Insurance coverage varies widely. Some plans cover it readily for documented hyperemesis gravidarum, while others require extensive prior authorization or deny coverage altogether, particularly because the therapy is still considered experimental by some guidelines. If your provider recommends a pump, having them document the severity of your condition and the failure of other treatments strengthens the case for insurance approval.